News & Events zu Cognition Therapeutics Inc (CGTX)CGTXCognition Therapeutics Inc

Cognition Estimates Sufficient Cash to Fund Operations into Q4 2027

Estimates that it has sufficient cash to fund operations and capital expenditures into the fourth quarter of 2027. Lisa Ricciardi, Cognition's president and CEO stated, "The work we conducted with the Office of Neuroscience at the FDA during 2026 culminated in the development of a trial protocol for a planned registrational study of zervimesine (CT1812) in people with dementia with Lewy bodies. We are now evaluating our plans for manufacturing, site selection, and patient recruitment. At the same time, we are working with our collaborators at the Alzheimer's Clinical Trial Consortium (ACTC) to prepare for the conclusion of the Phase 2 START Study in people with MCI and early Alzheimer's disease. Top-line results from START are anticipated in the second half of 2027 and will inform our plans for zervimesine in Alzheimer's disease."

Cognition Therapeutics Aligns with FDA to Advance Phase 3 DLB Study

Cognition Therapeutics has aligned with the U.S. FDA on key elements of a Phase 3 study in dementia with Lewy bodies including patient selection, dose, duration, and endpoints. The planned registrational study is expected to enroll participants with mild-to-moderate DLB who will be randomized to receive either 100 mg of once-daily oral zervimesine or placebo for nine months. "Over the course of the year, we have had collaborative discussions with FDA's Divisions of Neurology and Psychiatry within the Office of Neuroscience," stated Lisa Ricciardi, president and CEO of Cognition. "With FDA's alignment on trial design, we are completing a protocol to support the planned registrational study in DLB, a disease with no approved treatments."

Cognition Therapeutics Granted Patent for Novel Zervimesine Form

Cognition Therapeutics announced that the United States Patent and Trademark Office has granted the company a patent covering a novel crystalline form, or polymorph, of zervimesine (CT1812), the company's lead drug candidate. The patent has a natural expiration of 2045. Upon zervimesine's approval by the U.S. FDA, the patent may be eligible for an extension of up to five additional years.